Virological response to highly active antiretroviral therapy in patients infected with human immunodeficiency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the gambia and emergence of drug-resistant variants

Journal of Clinical Microbiology

Volumn 47, Issue 7, 2009, Pages 2200-2208

  Jallow, Sabelle ^a,b   Alabi, Abraham ^a   Sarge Njie, Ramu ^a   Peterson, Kevin ^a   Whittle, Hilton ^a   Corrah, Tumani ^a   Jaye, Assan ^a   Cotten, Matthew ^a   Vanham, Guido ^b,c   McConkey, Samuel J ^a,e   Rowland Jones, Sarah ^a,d   Janssens, Wouter ^b  

^a MEDICAL RESEARCH COUNCIL LABORATORIES   (Gambia)

^b INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^c UNIVERSITY OF ANTWERP   (Belgium)

^d JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^e ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE; RNA DIRECTED DNA POLYMERASE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GAMBIA; GENE MUTATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS 2 INFECTION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REBOUND; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; GAMBIA; HIV INFECTIONS; HIV PROTEASE; HIV REVERSE TRANSCRIPTASE; HIV-1; HIV-2; HUMANS; LAMIVUDINE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; PYRIMIDINONES; RITONAVIR; SEQUENCE ANALYSIS, DNA; TREATMENT OUTCOME; VIRAL LOAD; ZIDOVUDINE;

HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 67650034266     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.01654-08     Document Type: Article

References (55)

1. + cell counts, and drug resistance profiles of patients treated in Abidjan, Cote d'Ivoire. AIDS 17(Suppl. 3):S49-S54.
2. Adjorlolo-Johnson, G., K. M. De Cock, E. Ekpini, K. M. Vetter, T. Sibailly, K. Brattegaard, D. Yavo, R. Doorly, J. P. Whitaker, L. Kestens, et al. 1994. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 272:462-466.
3. Andreasson, P. A., F. Dias, A. Naucler, S. Andersson, and G. Biberfeld. 1993. A prospective study of vertical transmission of HIV-2 in Bissau, Guinea-Bissau. AIDS 7:989-993.
4. Berry, N., K. Ariyoshi, S. Jaffar, S. Sabally, T. Corrah, R. Tedder, and H. Whittle. 1998. Low peripheral blood viral HIV-2 RNA in individuals with high CD4 percentage differentiates HIV-2 from HIV-1 infection. J. Hum. Virol. 1:457-468.
5. Bock, P. J., and D. M. Markovitz. 2001. Infection with HIV-2. AIDS 15(Suppl. 5):S35-S45.
6. Brandin, E., L. Lindborg, K. Gyllensten, C. Brostrom, L. Hagberg, M. Gisslen, B. Tuvesson, A. Blaxhult, and J. Albert. 2003. pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy. AIDS Res. Hum. Retrovir. 19:543-550.
7. Brower, E. T., U. M. Bacha, Y. Kawasaki, and E. Freire. 2008. Inhibition of HIV-2 protease by HIV-1 protease inhibitors in clinical use. Chem. Biol. Drug Des. 71:298-305.
8. Clavel, F., D. Guetard, F. Brun-Vezinet, S. Chamaret, M. A. Rey, M. O. Santos-Ferreira, A. G. Laurent, C. Dauguet, C. Katlama, C. Rouzioux, et al. 1986. Isolation of a new human retrovirus from West African patients with AIDS. Science 233:343-346.
9. Colson, P., M. Henry, N. Tivoli, H. Gallais, J. A. Gastaut, J. Moreau, and C. Tamalet. 2005. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southeastern France. J. Med. Virol. 75:381-390.
10. Colson, P., M. Henry, C. Tourres, D. Lozachmeur, H. Gallais, J. A. Gastaut, J. Moreau, and C. Tamalet. 2004. Polymorphism and drug-selected mutations in the protease gene of human immunodeficiency virus type 2 from patients living in Southern France. J. Clin. Microbiol. 42:570-577.
11. Damond, F., F. Brun-Vezinet, S. Matheron, G. Peytavin, P. Campa, S. Pueyo, F. Mammano, S. Lastere, I. Farfara, F. Simon, G. Chene, and D. Descamps. 2005. Polymorphism of the human immunodeficiency virus type 2 (HIV-2) protease gene and selection of drug resistance mutations in HIV-2-infected patients treated with protease inhibitors. J. Clin. Microbiol. 43:484-487.
12. Damond, F., S. Lariven, B. Roquebert, S. Males, G. Peytavin, G. Morau, D. Toledano, D. Descamps, F. Brun-Vezinet, and S. Matheron. 2008. Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 22:665-666.
13. da Silva, B. F., C. H. McMillan, P. J. Eron, R. Wolfe, M. Gulick, M. Glesby, C. Thompson, A. C. Benson, M. White, H. Albrecht, K. Kessler, K. Niemi, D. King, M. Calhoun, G. King, and S. Hanna. 2005. Seven year follow-up of a lopinavir/ritonavir (LPV/r)-based regimen in antiretroviral (ARV)-naïve subjects, abstr. PE7.9/3. Tenth European AIDS Conference.
14. Descamps, D., G. Collin, F. Letourneur, C. Apetrei, F. Damond, I. Loussert-Ajaka, F. Simon, S. Saragosti, and F. Brun-Vezinet. 1997. Susceptibility of human immunodeficiency virus type 1 group O isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. J. Virol. 71:8893-8898.
15. Friend, J., N. Parkin, T. Liegler, J. N. Martin, and S. G. Deeks. 2004. Isolated lopinavir resistance after virological rebound of a ritonavir/lopinavir-based regimen. AIDS 18:1965-1966.
16. Gulick, R. M., J. W. Mellors, D. Havlir, J. J. Eron, C. Gonzalez, D. Mc-Mahon, D. D. Richman, F. T. Valentine, L. Jonas, A. Meibohm, E. A. Emini, and J. A. Chodakewitz. 1997. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N. Engl. J. Med. 337:734-739.
17. Hammer, S. M., K. E. Squires, M. D. Hughes, J. M. Grimes, L. M. Demeter, J. S. Currier, J. J. Eron, Jr., J. E. Feinberg, H. H. Balfour, Jr., L. R. Deyton, J. A. Chodakewitz, and M. A. Fischl for the AIDS Clinical Trials Group 320 Study Team. 1997. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N. Engl. J. Med. 337:725-733.
18. Hansmann, A., M. F. Schim van der Loeff, S. Kaye, A. A. Awasana, R. Sarge-Njie, D. O'Donovan, K. Ariyoshi, A. Alabi, P. Milligan, and H. C. Whittle. 2005. Baseline plasma viral load and CD4 cell percentage predict survival in HIV-1- and HIV-2-infected women in a community-based cohort in The Gambia. J. Acquir. Immune Defic. Syndr. 38:335-341.
19. Hightower, M., and E. G. Kallas. 2003. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review. Braz. J. Infect. Dis. 7:7-15.
20. HIV Infection in Newborns French Collaborative Study Group. 1994. Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. Pediatr. Infect. Dis. J. 13:502-506.
21. Holmgren, B., Z. da Silva, P. Vastrup, O. Larsen, S. Andersson, H. Ravn, and P. Aaby. 2007. Mortality associated with HIV-1, HIV-2, and HTLV-I single and dual infections in a middle-aged and older population in Guinea-Bissau. Retrovirology 4:85.
22. Isaka, Y., S. Miki, S. Kawauchi, A. Suyama, H. Sugimoto, A. Adachi, T. Miura, M. Hayami, O. Yoshie, T. Fujiwara, and A. Sato. 2001. A single amino acid change at Leu-188 in the reverse transcriptase of HIV-2 and SIV renders them sensitive to non-nucleoside reverse transcriptase inhibitors. Arch. Virol. 146:743-755.
23. Jallow, S., S. Kaye, A. Alabi, A. Aveika, R. Sarge-Njie, S. Sabally, T. Corrah, H. Whittle, G. Vanham, S. Rowland-Jones, W. Janssens, and S. J. McConkey. 2006. Virological and immunological response to Combivir and emergence of drug resistance mutations in a cohort of HIV-2 patients in The Gambia. AIDS 20:1455-1458.
24. Jallow, S., S. Kaye, M. Schutten, E. Brandin, J. Albert, S. J. McConkey, T. Corrah, H. Whittle, G. Vanham, S. Rowland-Jones, and W. Janssens. 2007. Development and evaluation of an oligonucleotide ligation assay for detection of drug resistance-associated mutations in the human immunodeficiency virus type 2 pol gene. J. Clin. Microbiol. 45:1565-1571.
25. Jaye, A., R. Sarge-Njie, M. Schim van der Loeff, J. Todd, A. Alabi, S. Sabally, T. Corrah, and H. Whittle. 2004. No differences in cellular immune responses between asymptomatic HIV type 1- and type 2-infected Gambian patients. J. Infect. Dis. 189:498-505.
26. Johnson, V. A., F. Brun-Vezinet, B. Clotet, H. F. Gunthard, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2008. Update of the drug resistance mutations in HIV-1: Spring 2008. Top. HIV Med. 16:62-68.
27. Johnson, V. A., F. Brun-Vezinet, B. Clotet, D. R. Kuritzkes, D. Pillay, J. M. Schapiro, and D. D. Richman. 2006. Update of the drug resistance mutations in HIV-1: Fall 2006. Top. HIV Med. 14:125-130.
28. Kagan, R. M., M. D. Shenderovich, P. N. Heseltine, and K. Ramnarayan. 2005. Structural analysis of an HIV-1 protease I47A mutant resistant to the protease inhibitor lopinavir. Protein Sci. 14:1870-1878.
29. Kanki, P. J., K. U. Travers, S. MBoup, C. C. Hsieh, R. G. Marlink, A. Gueye-NDiaye, T. Siby, I. Thior, M. Hernandez-Avila, J. L. Sankalé, et al. 1994. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 343:943-946.
30. Kaye, S. 2003. Simple PCR-based method for synthesis of molecular calibrators and controls. Clin. Chem. 49:325-327.
31. Kempf, D. J., J. D. Isaacson, M. S. King, S. C. Brun, J. Sylte, B. Richards, B. Bernstein, R. Rode, and E. Sun. 2002. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir. Ther. 7:165-174.
32. Kuritzkes, D. R., R. L. Bassett, J. D. Hazelwood, H. Barrett, R. A. Rhodes, R. K. Young, and V. A. Johnson. 2004. Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens. J. Acquir. Immune Defic. Syndr. 36:600-603.
33. Little, S. J., S. Holte, J. P. Routy, E. S. Daar, M. Markowitz, A. C. Collier, R. A. Koup, J. W. Mellors, E. Connick, B. Conway, M. Kilby, L. Wang, J. M. Whitcomb, N. S. Hellmann, and D. D. Richman. 2002. Antiretroviral-drug resistance among patients recently infected with HIV. N. Engl. J. Med. 347:385-394.
34. MacNeil, A., A. D. Sarr, J. L. Sankalé, S. T. Meloni, S. Mboup, and P. Kanki. 2007. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J. Virol. 81:5325-5330.
35. Manasa, J., H. Musabaike, C. Masimirembwa, E. Burke, R. Luthy, and J. Mudzori. 2007. Evaluation of the Partec flow cytometer against the BD FACSCalibur system for monitoring immune responses of human immunodeficiency virus-infected patients in Zimbabwe. Clin. Vaccine Immunol. 14:293-298.
36. + T-cell determinations with CD45 gating for persons infected with human immunodeficiency virus. MMWR Recommend. Rep. 52(RR-2):1-13.
37. Masquelier, B., D. Breilh, D. Neau, S. Lawson-Ayayi, V. Lavignolle, J. M. Ragnaud, M. Dupon, P. Morlat, F. Dabis, and H. Fleury. 2002. Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob. Agents Chemother. 46: 2926-2932.
38. Masse, S., X. Lu, T. Dekhtyar, L. Lu, G. Koev, F. Gao, H. Mo, D. Kempf, B. Bernstein, G. J. Hanna, and A. Molla. 2007. In vitro selection and characterization of human immunodeficiency virus type 2 with decreased susceptibility to lopinavir. Antimicrob. Agents Chemother. 51:3075-3080.
39. Mo, H., M. S. King, K. King, A. Molla, S. Brun, and D. J. Kempf. 2005. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates. J. Virol. 79:3329-3338.
40. Most, J., L. Spotl, M. Sarcletti, W. Vogetseder, M. P. Dierich, and R. Zangerle. 1994. Differences in heterosexual transmission of HIV-1 and HIV-2. Lancet 344:1572-1573.
41. Mullins, C., G. Eisen, S. Popper, A. Dieng Sarr, J. L. Sankalé, J. J. Berger, S. B. Wright, H. R. Chang, G. Coste, T. P. Cooley, P. Rice, P. R. Skolnik, M. Sullivan, and P. J. Kanki. 2004. Highly active antiretroviral therapy and viral response in HIV type 2 infection. Clin. Infect. Dis. 38:1771-1779.
42. Nkengasong, J. N., C. Adjé-Touré, and P. J. Weidle. 2004. HIV antiretroviral drug resistance in Africa. AIDS Rev. 6:4-12.
43. Ntemgwa, M., B. G. Brenner, M. Oliveira, D. Moisi, and M. A. Wainberg. 2007. Natural polymorphisms in the human immunodeficiency virus type 2 protease can accelerate time to development of resistance to protease inhibitors. Antimicrob. Agents Chemother. 51:604-610.
44. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg for the HIV Outpatient Study Investigators. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
45. Pichova, I., J. Weber, J. Litera, J. Konvalinka, J. Vondrasek, M. Soucek, P. Strop, P. Majer, A. M. Heuser, and H. G. Kraeusslich. 1997. Peptide inhibitors of HIV-1 and HIV-2 proteases: a comparative study. Leukemia 11(Suppl. 3):120-122.
46. Pomerantz, R. J., and D. L. Horn. 2003. Twenty years of therapy for HIV-1 infection. Nat. Med. 9:867-873.
47. Popper, S. J., A. D. Sarr, K. U. Travers, A. Gueye-Ndiaye, S. Mboup, M. E. Essex, and P. J. Kanki. 1999. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J. Infect. Dis. 180:1116-1121.
48. Poveda, E., B. Rodes, C. Toro, and V. Soriano. 2004. Are fusion inhibitors active against all HIV variants? AIDS Res. Hum. Retrovir. 20:347-348.
49. Rodés, B., A. Holguin, V. Soriano, M. Dourana, K. Mansinho, F. Antunes, and J. Gonzalez-Lahoz. 2000. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. J. Clin. Microbiol. 38:1370-1374.
50. Rodés, B., J. Sheldon, C. Toro, V. Jimenez, M. A. Alvarez, and V. Soriano. 2006. Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. J. Antimicrob. Chemother. 57:709-713.
51. Schim van der Loeff, M. F., and P. Aaby. 1999. Towards a better understanding of the epidemiology of HIV-2. AIDS 13(Suppl. A):S69-S84.
52. Schim van der Loeff, M. F., S. Jaffar, A. A. Aveika, S. Sabally, T. Corrah, E. Harding, A. Alabi, A. Bayang, K. Ariyoshi, and H. C. Whittle. 2002. Mortality of HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients in a clinic-based cohort in The Gambia. AIDS 16:1775-1783.
53. Schutten, M., M. E. van der Ende, and A. D. Osterhaus. 2000. Antiretroviral therapy in patients with dual infection with human immunodeficiency virus types 1 and 2. N. Engl. J. Med. 342:1758-1760.
54. Shaharabany, M., and A. Hizi. 1992. The catalytic functions of chimeric reverse transcriptases of human immunodeficiency viruses type 1 and type 2. J. Biol. Chem. 267:3674-3678.
55. Tomasselli, A. G., J. O. Hui, T. K. Sawyer, D. J. Staples, C. Bannow, I. M. Reardon, W. J. Howe, D. L. DeCamp, C. S. Craik, and R. L. Heinrikson. 1990. Specificity and inhibition of proteases from human immunodeficiency viruses 1 and 2. J. Biol. Chem. 265:14675-14683.